Lv5
1100 积分 2021-08-02 加入
Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study
2天前
已完结
Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial
2天前
求助中
Dual-modal immunoassay for prostate cancer-derived exosomes enabled by a black phosphorus/silver SERS substrate and Yb/Er co-doped NaGdF4 UCL nanoprobes
9天前
已关闭
Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients’ selection
23天前
已完结
Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)
23天前
已完结
Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma
2个月前
已完结
Sintilimab Plus Axitinib for Advanced Fumarate Hydratase–Deficient Renal Cell Carcinoma
2个月前
已完结
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study
2个月前
已完结
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
2个月前
已完结
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
2个月前
已完结
皖公网安备34019202002308
